Status:

TERMINATED

Coxib-inhibition of Duodenal Polyp Growth in FAP

Lead Sponsor:

Oslo University Hospital

Conditions:

Duodenal Polyposis

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

PHASE3

Brief Summary

Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would s...

Eligibility Criteria

Inclusion

  • FAP patient with previous colectomy and confirmed polyposis

Exclusion

  • Pregnancy
  • Malignancy
  • NSAID hypersensitivity

Key Trial Info

Start Date :

September 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2004

Estimated Enrollment :

38 Patients enrolled

Trial Details

Trial ID

NCT00844727

Start Date

September 1 2003

End Date

April 1 2004

Last Update

July 6 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dept of Medicine, Rikshospitalet

Oslo, Oslo County, Norway, 0027

Coxib-inhibition of Duodenal Polyp Growth in FAP | DecenTrialz